Management of Metastatic and Relapsed Disease
Metastatic osteosarcoma, particularly when it spreads to the lungs, remains the greatest clinical challenge in 2026.
The standard US approach for lung nodules is Metastasectomy—the surgical removal of all visible nodules. When surgery is not enough, second-line targeted therapies such as Cabozantinib or Regorafenib (Multi-Kinase Inhibitors) are employed to slow disease progression. US clinical trials in 2026 are also investigating Inhaled Chemotherapy and CAR-T cell therapies (targeting B7-H3 or HER2) to deliver more potent treatments directly to lung metastases while minimizing systemic toxicity.
2 Views